Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | HTT | P42858 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2048722 | 0.82 | BCAT2 (0.52) | KMT2AMEN1HTTALDH1A1NPC1 | |
| SCHEMBL30310050 | 0.82 | BCAT2 (0.52) | KMT2AMEN1HTTALDH1A1NPC1 | |
| SCHEMBL30310049 | 0.82 | BCAT2 (0.52) | KMT2AMEN1HTTALDH1A1NPC1 | |
| SCHEMBL5687024 | 0.81 | MEN1 (0.48) | KMT2AMEN1P2RX3BACE1 | |
| SCHEMBL29415402 | 0.81 | KMT2A (0.45) | KMT2AMEN1HTTALDH1A1ATM | |
| SCHEMBL4797475 | 0.81 | MEN1 (0.39) | KMT2AMEN1P2RX3BACE1 | |
| SCHEMBL4797479 | 0.81 | MEN1 (0.50) | KMT2AMEN1ALDH1A1NPC1RAB9A | |
| SCHEMBL2751024 | 0.80 | ALDH1A1 (0.46) | KMT2AMEN1HTTALDH1A1GAA | |
| SCHEMBL20216125 | 0.80 | SMN1; SMN2 (0.45) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL12261860 | 0.80 | MEN1 (0.40) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| US-9987276-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-06-05 | — | — | US | disclosed |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-13 | — | — | US | disclosed |
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RES INC (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160303121-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-20 | — | — | US | disclosed |
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2016-09-29 | — | — | US | disclosed |
| US-9409921-B2 | 2,4-disubstituted pyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9393246-B2 | 4,6-disubstituted pyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9296737-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296704-B2 | Substituted pyrimidines as protein kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-8178540-B2 | Pyrimidylmethyl-sulfonamide compounds | BASF SE (DE) | 2012-05-15 | — | — | US | disclosed |
| US-20110230494-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7989465-B2 | 4,6-disubstituted pyrimidines useful as kinase inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100077512-A1 | Pyridazin-4-ylmethyl-sulfonamides used as Fungicides and Against Arthropods | BASF SE (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20100069243-A1 | Pyrimidylmethyl-Sulfonamide Compounds | BASF SE (DE) | 2010-03-18 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | KMT2A 3318/4885MEN1 606/4885HTT 89/4885 |
| US-20160303121-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KMT2A 3318/4885MEN1 606/4885HTT 89/4885 |
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KMT2A 3318/4885MEN1 606/4885HTT 89/4885 |
| US-20100069243-A1 | Pyrimidylmethyl-Sulfonamide Compounds | TPMT, NISCH, PPA1 | KMT2A 702/4885MEN1 2487/4885HTT 2587/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KMT2A 3318/4885MEN1 606/4885HTT 89/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KMT2A 3318/4885MEN1 606/4885HTT 89/4885 |
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KMT2A 3318/4885MEN1 606/4885HTT 89/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KMT2A 3318/4885MEN1 606/4885HTT 89/4885 |
| US-20100077512-A1 | Pyridazin-4-ylmethyl-sulfonamides used as Fungicides and Against Arthropods | PIR, PRDX4, PRDX2 | KMT2A 388/4885MEN1 2802/4885HTT 3530/4885 |
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KMT2A 3318/4885MEN1 606/4885HTT 89/4885 |
| US-20110230494-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KMT2A 3318/4885MEN1 606/4885HTT 89/4885 |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KMT2A 3318/4885MEN1 606/4885HTT 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.